NCT06956001 2026-02-12
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
Allist Pharmaceuticals, Inc.
Phase 3 Recruiting
Allist Pharmaceuticals, Inc.
Tang-Du Hospital
Shanghai Yizhong Pharmaceutical Co., Ltd.
Shanghai Gebaide Biotechnology Co., Ltd.
Telik